Medifast Inc MED
We take great care to ensure that the data presented and summarized in this overview for MEDIFAST INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MED
View all-
Black Rock Inc. New York, NY1.75MShares$43.8 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.26MShares$31.5 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.23MShares$30.8 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny797KShares$19.9 Million0.05% of portfolio
-
Invesco Ltd. Atlanta, GA550KShares$13.8 Million0.0% of portfolio
-
State Street Corp Boston, MA430KShares$10.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY425KShares$10.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny300KShares$7.51 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX291KShares$7.26 Million0.0% of portfolio
-
Hotchkis & Wiley Capital Management LLC Los Angeles, CA288KShares$7.21 Million0.04% of portfolio
Latest Institutional Activity in MED
Top Purchases
Top Sells
About MED
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
Insider Transactions at MED
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 15
2024
|
Daniel R Chard Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,409
-1.11%
|
$122,724
$36.61 P/Share
|
Mar 15
2024
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-1.67%
|
$4,824
$36.61 P/Share
|
Mar 15
2024
|
James P. Maloney Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
616
-1.03%
|
$22,176
$36.61 P/Share
|
Mar 13
2024
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,565
+38.77%
|
-
|
Mar 13
2024
|
James P. Maloney Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,718
+30.2%
|
-
|
Mar 13
2024
|
Daniel R Chard Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
45,087
+30.4%
|
-
|
Mar 08
2024
|
Scott Schlackman Director |
SELL
Open market or private sale
|
Direct |
4,053
-18.55%
|
$158,067
$39.43 P/Share
|
Mar 08
2024
|
Scott Schlackman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+9.9%
|
$35,100
$27.68 P/Share
|
Feb 14
2024
|
James P. Maloney Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
648
-5.36%
|
$33,696
$52.68 P/Share
|
Feb 14
2024
|
James P. Maloney Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,328
+16.16%
|
-
|
Feb 14
2024
|
Daniel R Chard Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,471
-8.6%
|
$284,492
$52.68 P/Share
|
Feb 14
2024
|
Daniel R Chard Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
16,486
+20.58%
|
-
|
Nov 07
2023
|
Scott Schlackman Director |
BUY
Open market or private purchase
|
Direct |
52
+0.49%
|
$3,536
$68.89 P/Share
|
Nov 07
2023
|
Michael A. Hoer Director |
BUY
Open market or private purchase
|
Direct |
49
+0.58%
|
$3,332
$68.89 P/Share
|
Nov 07
2023
|
Andrea B Thomas Director |
BUY
Open market or private purchase
|
Direct |
50
+0.79%
|
$3,400
$68.89 P/Share
|
Nov 07
2023
|
Jeffrey J Brown Director |
BUY
Open market or private purchase
|
Direct |
58
+0.99%
|
$3,944
$68.89 P/Share
|
Nov 03
2023
|
Jeffrey J Brown Director |
BUY
Open market or private purchase
|
Indirect |
96
+2.22%
|
$6,720
$70.55 P/Share
|
Oct 06
2023
|
Constance J. Hallquist |
SELL
Open market or private sale
|
Indirect |
5,613
-72.29%
|
$409,749
$73.87 P/Share
|
Sep 13
2023
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
10
-0.67%
|
$810
$81.08 P/Share
|
Aug 15
2023
|
Jeffrey J Brown Director |
SELL
Open market or private sale
|
Indirect |
23,162
-71.22%
|
$2,084,580
$90.13 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 89.6K shares |
---|---|
Open market or private purchase | 1.97K shares |
Exercise of conversion of derivative security | 4.87K shares |
Open market or private sale | 48K shares |
---|---|
Payment of exercise price or tax liability | 11.4K shares |